| __timestamp | Geron Corporation | Travere Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 16758000 | 59644696 |
| Thursday, January 1, 2015 | 17793000 | 79541000 |
| Friday, January 1, 2016 | 18761000 | 98015000 |
| Sunday, January 1, 2017 | 19287000 | 103958000 |
| Monday, January 1, 2018 | 18707000 | 103654000 |
| Tuesday, January 1, 2019 | 20893000 | 128951000 |
| Wednesday, January 1, 2020 | 25678000 | 135799000 |
| Friday, January 1, 2021 | 29665000 | 149883000 |
| Saturday, January 1, 2022 | 43628000 | 220206000 |
| Sunday, January 1, 2023 | 69135000 | 265542000 |
Igniting the spark of knowledge
In the competitive landscape of biotechnology, understanding financial health is crucial. Geron Corporation and Travere Therapeutics, Inc. have shown distinct trends in their Selling, General, and Administrative (SG&A) expenses from 2014 to 2023. Over this period, Travere Therapeutics consistently outpaced Geron Corporation, with SG&A expenses growing by approximately 345%, compared to Geron's 312% increase. Notably, in 2023, Travere's expenses reached nearly four times that of Geron, highlighting its aggressive expansion strategy. This trend reflects broader industry dynamics, where companies invest heavily in administrative and sales functions to drive growth. As the biotech sector continues to evolve, monitoring these financial metrics provides valuable insights into corporate strategies and market positioning. The data underscores the importance of strategic financial management in sustaining competitive advantage in the biotech industry.
Operational Costs Compared: SG&A Analysis of Merck & Co., Inc. and Geron Corporation
Who Optimizes SG&A Costs Better? Incyte Corporation or Travere Therapeutics, Inc.
Comparing SG&A Expenses: Intra-Cellular Therapies, Inc. vs Geron Corporation Trends and Insights
Cost Management Insights: SG&A Expenses for Cytokinetics, Incorporated and Geron Corporation
Cost Management Insights: SG&A Expenses for Veracyte, Inc. and Geron Corporation
Operational Costs Compared: SG&A Analysis of Veracyte, Inc. and Travere Therapeutics, Inc.
Cost Management Insights: SG&A Expenses for ACADIA Pharmaceuticals Inc. and Geron Corporation
Cost Management Insights: SG&A Expenses for MorphoSys AG and Geron Corporation
HUTCHMED (China) Limited or Travere Therapeutics, Inc.: Who Manages SG&A Costs Better?
Who Optimizes SG&A Costs Better? Geron Corporation or Wave Life Sciences Ltd.
Iovance Biotherapeutics, Inc. or Travere Therapeutics, Inc.: Who Manages SG&A Costs Better?
Selling, General, and Administrative Costs: Travere Therapeutics, Inc. vs BioCryst Pharmaceuticals, Inc.